Exact Sciences (EXAS) is a diagnostic company offering non-invasive colorectal cancer screening with their flagship product, Cologuard. Today, the company's valuation stands at around $14B and they will need to be aggressive in increasing the product's market share in order to justify this valuation. Recently, they acquired Genomic Health, which will provide them with other sources of revenue. They are also making good progress with a liquid biopsy test for Hepatocellular Carcinoma. Don't forget to like and subscribe! Follow me on twitter @matthewlepoire Email me: [email protected] www.breakingbiotech.com biotech #EXAS #cancer Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech